A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and “pan-leukemia” antigens
暂无分享,去创建一个
H. Rammensee | S. Stevanović | O. Kohlbacher | T. Brümmendorf | L. Kanz | D. Niederwieser | H. Salih | L. Backert | J. Walz | H. Schuster | D. Kowalewski | C. Berlin | M. Schemionek | S. Walz | K. Weisel | M. Neidert | V. Vucinic | H. Schuster | V. Vučinić
[1] M. Shipp,et al. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Ton N. Schumacher,et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires , 2016, Science.
[3] Anthony Walker,et al. Commercialization of cellular immunotherapies for cancer. , 2016, Biochemical Society transactions.
[4] M. Nielsen,et al. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets , 2016, Genome Medicine.
[5] J. Gartner,et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients , 2016, Nature Medicine.
[6] H. Rammensee,et al. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy , 2015, Leukemia.
[7] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[8] A. Bagg,et al. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. , 2015, The New England journal of medicine.
[9] Oliver Kohlbacher,et al. The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. , 2015, Blood.
[10] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[11] David C. Smith,et al. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] H. Rammensee,et al. Antileukemia T-cell responses in CLL – We don't need no aberration , 2015, Oncoimmunology.
[14] X. Wang,et al. Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies , 2015, Cancer Gene Therapy.
[15] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[16] L. Jensen,et al. Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation* , 2015, Molecular & Cellular Proteomics.
[17] T. Lumley,et al. gplots: Various R Programming Tools for Plotting Data , 2015 .
[18] Hans-Georg Rammensee,et al. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL) , 2014, Proceedings of the National Academy of Sciences.
[19] M. Millenson,et al. Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies , 2014 .
[20] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[21] Maxim N. Artyomov,et al. Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.
[22] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[23] S Walz,et al. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy , 2014, Leukemia.
[24] I. Melero,et al. Orchestrating immune check-point blockade for cancer immunotherapy in combinations. , 2014, Current opinion in immunology.
[25] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[26] R. Guest,et al. Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial , 2014, Cancer Immunology, Immunotherapy.
[27] Jennifer Couzin-Frankel,et al. Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.
[28] H. Rammensee,et al. HLA Ligandome Analysis Of Chronic Myeloid Leukemia (CML), Revealed Novel Tumor Associated Antigens For Peptide Based Immunotherapy , 2013 .
[29] M. Stratton,et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[31] A. Darzi,et al. Intraoperative Tissue Identification Using Rapid Evaporative Ionization Mass Spectrometry , 2013, Science Translational Medicine.
[32] J. Riley. Combination checkpoint blockade--taking melanoma immunotherapy to the next level. , 2013, The New England journal of medicine.
[33] Jimmy Lin,et al. Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.
[34] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[35] S. Stevanović,et al. Biochemical large-scale identification of MHC class I ligands. , 2013, Methods in molecular biology.
[36] Hiroaki Tanaka,et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival , 2012, Nature Medicine.
[37] Hans-Georg Rammensee,et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. , 2012, Brain : a journal of neurology.
[38] S. Riddell,et al. Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia , 2011, Immunology and cell biology.
[39] B. Levine,et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. , 2010, Cancer research.
[40] Ilan Beer,et al. Soluble plasma HLA peptidome as a potential source for cancer biomarkers , 2010, Proceedings of the National Academy of Sciences.
[41] T. Habermann,et al. Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma , 2009, Clinical Cancer Research.
[42] H. Rammensee,et al. HLA ligand profiles of primary renal cell carcinoma maintained in metastases , 2009, Cancer Immunology, Immunotherapy.
[43] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[44] Donald Kennedy,et al. Breakthrough of the Year , 2007, Science.
[45] M. Labopin,et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] William Stafford Noble,et al. Semi-supervised learning for peptide identification from shotgun proteomics datasets , 2007, Nature Methods.
[47] Hans-Georg Rammensee,et al. Distorted Relation between mRNA Copy Number and Corresponding Major Histocompatibility Complex Ligand Density on the Cell Surface*S , 2007, Molecular & Cellular Proteomics.
[48] Gábor Csárdi,et al. The igraph software package for complex network research , 2006 .
[49] J. Byrne,et al. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation , 2005, Bone Marrow Transplantation.
[50] N. Schmitz,et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. , 2004, Blood.
[51] C. Hillyer,et al. Donor lymphocyte infusion therapy. , 2002, Transfusion medicine reviews.
[52] M. Oudshoorn,et al. HLA gene haplotype frequencies in bone marrow donors worldwide registries. , 1997, Human immunology.
[53] R. Storb,et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.